Antihistamines in allergic rhinitis;Leki przeciwhistaminowe w alergicznych niezytach nosa

Otolaryngologia Polska

Volumn 61, Issue 4, 2007, Pages 522-526

  Kruszewski, Jerzy ^a  

^a Klinika Chorob Infekcyjnych i Alergologii   (Poland)

Author keywords

Allergic rhinitis; Antihistamines; Efficacy

Indexed keywords

EID: 36749087495     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0030-6657(07)70477-8     Document Type: Article

References (33)

1. Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE i wsp. GA2LEN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006; 61: 1086-1096.
2. Samoliński B, Buczyłko K, Grzelewska-Rzymowska I, Tarchalska-Kryńska B. Leki przeciwhistaminowe w alergicznym nieżycie nosa. W: Górski P, Grzelewska-Rzymowska I, Kruszewski J, red. Leki przeciwhistaminowe. Wyd. 2. Bruksela: Seria; 2005. s. 67-86.
3. Silny W, Glińki W, Czarnrecka-Operacz; M, Samochcki Z, Wilkowska A. Leki przeciwhistaminowe w terapii dermatologicznej. W: Górski P, Grzelewska-Rzymowska I, Kruszewski J, red. Leki przeciwhistaminowe. Wyd. 2. Bruksela: Seria; 2005. s. 101-121.
4. Grimfeld A, Holgate ST, Canonica GW, Bonini S, Borres MP i wsp. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia. I Study. Clin Exp Allergy 2004; 34: 1665-1672.
5. Sutter AL Lemiengre M, Campbell H, Mackinnon HE Antihistamines for the common cold. Cochrane Database Syst Rev 2003; (3): CD001267.
6. Sharp HJ, Denman D, Puumala S, Leopold DA. Treatment of acute and chronic rhinosinusitis in the United States, 1999-2002. Arch Otolaryngol Head Neck Surg 2007; 133: 260-265.
7. Górski P, Grzelewska-Rzymowska I, Kruszewski J. Leki przeciwhistaminowe. Wyd. 2. Bruksela: Seria; 2005.
8. Kaliner MA, White MV, Economides A, Crisalida T, Hale M, i wsp. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol 2003; 90: 629-634.
9. Kruszewski J, Kłos K, Sułek K. Hamowanie pohistaminowego skórnego babla, rumienia i przepływu włośniczkowego podczas przewlekłego (przez 180 dni) stosowania cetyryzyny w dawce 10 mg/dobe. Merk Pol 2005; 19: 758-760.
10. Kruszewski J, Kłos K, Sułek K. Dynamika. hamowania pohistaminowego babla po podaniu zalecanych dawek: 10 mg cetryzyny, 10 mg loratadyny, 5 mg desloratadyny, 120 i 180 mg feksofenadyny, 5 mg lewocetryzyny - badanie randomizowane, kontrolowane placebo. Merk Pol 2006; 21: 443-448.
11. Kłos K, Kruszewski J, Kruszewski R, Sułek K. Wpływ 5-dniowego stosowania zalecanych dawek: 10 mg cetryzyny, 10 mg loratadyny, 5 mg desloratadyny, 120 i 180 mg feksofenadyny, 5 mg lewocetryzyny na. pohistaminowa reaktywność skóry - badanie randomizowane, kontrolowane placebo. Merk Pol 2006; 21: 449-453.
12. Ownby DR. Computerized measuremant of allergen-induced skin reactions. J Allergy Clin Immunol 1982; 69: 536-538.
13. Kruszewski J, Zuber J, Zmija J. Application of thermographic methods for estimation of skin prick test results. I. Temperature background of areas used for prick skin tests, optimum temperature ranges of liquid crystals mixtures. Int Rev Allergy Clin Immunol 1995; 1/5: 1-8.
14. Kruszewski J, Kłos K, Sułek K. hamowanie pohistaminowego skórnego babla, rumienia i przepływu włośniczkowego podczas przewlekłego (przez 180 dni) stosowania cetyryzyny w dawce 10 mg/dobe. Merk Pol. 2005; 19: 758-760.
15. Serup J. Diameter, thickness, area, and volume of skin-prick histamine weals measurement of skin thickness by 15 MHz A-mode Ultrasound. Allergy 1984; 39: 359-364.
16. Petersen LJ, Mosbech H, Skov PS. Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: Characterization of factors influencing histamine releasability. Allergy Clin Immunol 1996; 97: 672-679.
17. Larbig M, Burtin B, Martin L, Stamm H, Luettig B i wsp. Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine. Br J Clin Pharmacol 2006; 62: 158-164.
18. Devillier P Bousquet J. Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy? Clin Exp Allergy 2007; 37: 400-414.
19. Holgate S, Powell R, Jenkins M, Ali O. A treatment for allergic rhinitis: a view on the role of levocetirizine. Curr Med Res Opin 2005; 21: 1099-1106.
20. Seven B, Yoruk O, Varoglu E, Sutbeyaz Y. Evaluation of the effect of levocetirizine on nasal mucociliary clearance in allergic rhinitis patients by rhinoscintigraphy. Nucl Med Commun 2007; 28: 85-87.
21. Patou J, De Smedt H, van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006; 36: 972-981.
22. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patiency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006; 96: 363-368.
23. Schenkel EJ. Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis. Allergy Asthma Proc 2006; 27: 465-472.
24. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S i wsp. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5: 1800-1808.
25. Berkowitz RB, Braker S, Lutz C, Jones P, Meeves S i wsp. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96: 327-333.
26. Ratner P. Falques M, Chuecos F, Esbri R, Gispert J i wsp. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol 2005; 138: 312-318.
27. Stuebner P. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006; 96: 37-44.
28. Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis - a systematic review of randomized controlled trials. Clin Exp Allergy 2005; 35: 207-212.
29. Lee C, Corren J. Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. Expert Opin Pharmacother 2007; 8: 701-709.
30. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 664-671.
31. Barnes ML, Ward JH, Fardon TC, Lipworth Bj. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 2006; 36: 676-684.
32. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89: 479-84.
33. Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs. 2006; 66: 2309-2219.